AOD-9604 Real-World Response Rate: What Reddit, Clinical Data, and Patient Reports Actually Show

What the human data actually show

A 2026 review describes the main human obesity study: a 24-week trial of AOD9604 as an oral anti-obesity drug candidate, with 534 people enrolled and 502 randomized, that failed to show a significant benefit on the primary weight-loss endpoint [1]. The review is explicit about the limits of that result. It rests on sponsor-reported phase 2 findings rather than a peer-reviewed randomized trial, and no peer-reviewed efficacy paper for the trial itself exists [1]. The same review notes there are no robust human data for visceral-fat reduction or other metabolic benefit [1].

AOD-9604 was developed by an Australian company, Metabolic Pharmaceuticals, as an anti-obesity candidate, with phase IIa trials underway by February 2002 [2]. It never reached approval, and the obesity program was later dropped [2][1].

There is no approved dose [1]. The 24-week trial tested an oral drug candidate, not injected products sold on the gray market [1].

Why forum reports are hard to count

Product composition, dose, route and stacking practices are uncertain in unregulated supply chains [1]. Forum posts and vendor reviews do not come with that information, so they cannot be turned into a response rate. FDA's compounding page raises peptide impurities and characterization problems for AOD-9604 specifically [4].

What the animal studies found

In obese Zucker rats, oral AOD9604 at 500 micrograms/kg/day for 19 days cut body-weight gain to 15.8 g versus 35.6 g in controls — over half — and the treated animals' fat tissue showed higher lipolytic activity. Unlike chronic growth hormone, it did not harm insulin sensitivity on euglycemic clamp testing [3].

In obese mice, 14 days of intraperitoneal AOD9604 reduced body weight and body fat and raised beta-3 adrenergic receptor RNA to levels comparable with lean mice. In mice lacking that receptor, long-term treatment did not produce the same weight and lipolysis changes [7].

In that work, AOD9604's lipolytic action was not mediated directly through the beta-3 receptor, even though the peptide raised receptor expression [7]. In vitro, AOD9604 does not compete for the growth hormone receptor or drive cell proliferation through it [9]; the 2026 review notes preclinical work found no growth-hormone-receptor binding [1].

Safety: what FDA says about AOD-9604

FDA's page on bulk substances that may present significant safety risks when compounded lists AOD-9604 in its table of substances nominated and then withdrawn, which holds substances previously in category 2 whose nominators withdrew them [4]. FDA's stated concerns: compounded drugs containing AOD-9604 may pose significant immunogenicity risk for certain routes of administration, from peptide impurities and characterization problems; FDA has identified no, or only limited, safety information; and FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear [4]. FDA gives no details about those events, and removal from category 2 was not a finding that the substance is safe [4].

A 2026 review concludes that human evidence on AOD-9604 is limited and largely short-term [1]. A separate 2026 review of unapproved peptides used in sports medicine notes that many look favorable in animals while rigorous human safety data are scarce, with potential for serious harm [10].

Regulatory status

AOD-9604 is not an FDA-approved drug [2][1]. FDA's GRAS Notice Inventory contains no AOD-9604 notice, so the inventory does not show an FDA GRAS determination for it [11]. Belgian authorities and US investigators have found AOD-9604 in seized or confiscated vials, which shows it circulates on the gray market [12][13].

It appears in none of the three categories on FDA's list of bulk drug substances for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025), so FDA's category 1 policy — under which it generally does not act against compounders that meet certain conditions — does not cover it [14][15][16]. It is not one of the six peptides in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026, and it was not on the agenda of FDA's Pharmacy Compounding Advisory Committee meeting in July 2026 [17][18][19]. Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before marketing [19].

In sport, WADA's Prohibited List names AOD-9604 and hGH 176-191 in section S2.2.3, prohibited at all times, in and out of competition. It is on the 2026 List and remains on the 2027 List [5][20].